 |
More: American Academy of Allergy, Asthma & Immunology 2008 Annual Meeting Highlights of the American Academy of Allergy, Asthma & Immunology 2008 Annual Meeting CME/CE March 14 - 18, 2008, Philadelphia, Pennsylvania Author Information and Disclosures This activity is not sanctioned by, nor a part of, the American Academy of Allergy, Asthma & Immunology.
Release Date: May 8, 2008; Valid for credit through May 8, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Academy of Allergy, Asthma & Immunology. These materials and the related activity are not sanctioned by the American Academy of Allergy, Asthma & Immunology or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Discuss current diagnosis and treatment strategies for exercise-induced bronchospasm
- Review the current data on the role of natural killer T cells in asthma and allergies
- Discuss current research initiatives/trials in
asthma
Authors and Disclosures William W Storms, MD
Disclosure: William Storms, MD, has disclosed that he has received grants for research studies with Alcon Labs, ALTANA/Nycomed, Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Johnson & Johnson, MedPointe, Merck, Novartis, Pfizer, sanofi-aventis, and Schering. Dr.
Storms has also disclosed that he has served as a consultant for Adams, Alcon Labs, ALTANA/Nycomed, AstraZeneca, Consumer Reports/Consumers Union, Critical Therapeutics, Efficas, Exaeris, Genentech, Greer, GlaxoSmithKline, Hoffman-LaRoche, Isis, IVAX, King, MedPointe, Merck, NexCura, sanofi-aventis, Schering, Sepracor, Strategic Biosciences, Strategic Pharmaceutical Advisors, TEVA Colleqium, TREAT Foundation, UCB, and Wyeth. Dr. Storms has also disclosed that he has served on the
speaker's bureau for Abbott, Alcon Labs, AstraZeneca, Boehringer Ingelheim, MedPointe, Merck, Novartis, Pfizer, sanofi-aventis, and Schering. Erwin W. Gelfand, MD
Disclosure: Erwin W. Gelfand, MD, has disclosed that he has received grants for clinical research from Schering, Nycomed, and Novartis. Dr. Gelfand has also disclosed that he has served as an advisor or consultant to Teva, Schering, Nycomed, Merck, and
Novartis. Bradley E. Chipps, MD, FCCP
Disclosure: Bradley E. Chipps, MD, FCCP, has disclosed that he has received grants for clinical research from Aventis, Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Schering, Sepracor, and Merck, and that he has received grants for educational activities from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, and Novartis. Dr. Chipps has also disclosed that he has served
as an advisor or consultant to Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPointe, Novartis, Schering, Sepracor, and Merck, and that he has served on the speaker's bureau for Alcon, Aventis, Genentech, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MedPointe, Novartis, Pfizer, Schering, Sepracor, and Merck. Margaret A. Clark, RN, RRT-NPS
Disclosure: Margaret A. Clark, RN, RRT-NPS, has disclosed
no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
